Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells

Biochemical and Biophysical Research Communications

Volumn 309, Issue 3, 2003, Pages 625-630

  Bélizaire, Anna Karine ^a   Tchistiakova, Lioudmila ^a   St Pierre, Yves ^a   Alakhov, Valery ^b,c  

^a Supratek Pharma Inc   (Canada)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

^c Supratek Pharma Inc   (Canada)

Author keywords

Antigen presentation; ICAM 1; Peptide; Phage display

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; PEPTIDE; RECEPTOR;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL ADHESION; CELL INTERACTION; CELL SELECTION; CELL STRAIN COS7; CONTROLLED STUDY; DNA LIBRARY; ELUTION; ENDOTHELIUM; GENETIC TRANSFECTION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN TARGETING; SCREENING;

MURINAE;

EID: 0042831441     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.050     Document Type: Article

References (50)

1. Staunton D.E., Marlin S.D., Stratowa C., Dustin M.L., Springer T.A. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 52:1988;925-933.
2. Diamond M.S., Staunton D.E., de Fougerolles A.R., Stacker S.A., Garcia-Aguilar J., Hibbs M.L., Springer T.A. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol. 111:1990;3129-3139.
3. Rosenstein Y., Park J.K., Hahn W.C., Rosen F.S., Bierer B.E., Burakoff S.J. CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature. 354:1991;233-235.
4. Languino L.R., Plescia J., Duperray A., Brian A.A., Plow E.F., Geltosky J.E., Altieri D.C. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 73:1993;1423-1434.
5. McCourt P.A., Ek B., Forsberg N., Gustafson S. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J. Biol. Chem. 269:1994;30081-30084.
6. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., Springer T.A. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137:1986;245-254.
7. Nortamo P., Li R., Rekonen R., Timonen T., Prieto J., Patarroyo M., Gahmberg C.G. The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur. J. Immunol. 21:1991;2629-2632.
8. Cordell J.L., Pulford K., Rurley H., Jones M., Micklem K., Doussis I.A., Tyle X., Mayne K., Gatter K.C., Mason D.T. Cellular distribution of human leukocyte adhesion molecule ICAM-3. J. Clin. Pathol. 47:1994;143-147.
9. Dubey C., Croft M., Swain S.L. Costimulatory requirements of naïve CD4+ T-cells. ICAM-1 or B7-1 can costimulate naïve CD4 T-cell activation but both are required for optimum response. J. Immunol. 155:1995;45-57.
10. Chong A.S., Boussy I.A., Jang X.L., Lamas M., Graf L.H. Jr. CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol. 157:1994;92-105.
11. Gaglia J.L., Freenfield E.A., Mattoo A., Sharpe A.H., Feeman G.J., Kuchroo V.K. Intercellular adhesion molecule 1 is critical for activation of CD28-deficient cells. J. Immunol. 165:2000;6091-6098.
12. Harning R., Myer C., Merluzzi V.J. Monoclonal antibodies to lymphocyte function-associated antigen-1 inhibit invasion of human lymphoma and metastasis of murine lymphoma. Clin. Exp. Metastas. 11:1993;337-342.
13. Zahalka M.A., Okon E., Naor D. Blocking lymphoma invasiveness with a monoclonal antibody directed against the beta-chain of the leukocyte adhesion molecule (CD18). J. Immunol. 150:1993;4466-4477.
14. Aoudjit F., Potworowski E.F., Springer T.A., St-Pierre Y. Protection from lymphoma cell metastasis in ICAM-1 mutant mice: a posthoming event. J. Immunol. 161:1998;2333-2338.
15. Lalancette M., Aoudjit F., Potworowski E.F., St-Pierre Y. Resistance of ICAM-1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood. 95:2000;314-319.
16. Neumeister P., Eibl M., Zinke-Cerwenka W., Scarpatetti M., Sill H., Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann. Hemat. 80:2001;119-120.
17. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Anti-TNF therapy against congestive heart failure investigators. randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 107:2003;3133-3140.
18. Thomas G.E., Esteban J.M., Raubitschek A., Wong J.Y. Int. J. Radiat. Oncol. Biol. Phys. 31(3):1995;529-534 γ-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;529-534.
19. Thomas G.E., Esteban J.M., Raubitschek A., Wong J.Y. Int. J. Radiat. Oncol. Biol. Phys. 31(3):1995;529-534 γ-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;529-534.
20. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. Therapeutic cancer targeting peptides. Biopolymers. 66:2002;184-199. Review.
21. Popkov M., Lussier I., Medvedkine V., Esteve P.O., Alakhov V., Mandeville R. Multidrug-resistance drug-binding peptides generated by using a phage display library. Eur. J. Biochem. 251:1998;155-163.
22. St Pierre Y., Watts T.H. Characterization of the signaling function of MHC class II molecules during antigen presentation by B cells. J. Immunol. 147:1991;2875-2882.
23. Scheynius A., Camp R.L., Pure E. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. J. Immunol. 150:1993;655-663.
24. Ochietti B., Lemieux P., Kabanov A.V., Vinogradov S., St-Pierre Y., Alakhov V. Inducing neutrophil recruitment in the liver of ICAM-1-deficient mice using polyethyleneimine grafted with Pluronic P123 as an organ-specific carrier for transgenic ICAM-1. Gene. Ther. 9:2002;939-945.
25. Champagne B., Tremblay P., Cantin A., St Pierre Y. Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J. Immunol. 161:1998;6398-63405.
26. Takei F. Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2). J. Immunol. 134:1985;1403-1407.
27. Horley K.J., Carpenito C., Baker B., Takei F. Molecular cloning of murine intercellular adhesion molecule (ICAM-1). EMBO J. 8:1989;2889-2896.
28. Kumasaka T., Quinlan W.M., Doyle N.A., Condon T.P., Sligh J., Takei F., Beaudet A., Bennett C.F., Doerschuk C.M. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J. Clin. Invest. 97:1996;2362-2369.
29. Welply J.K., Steininger C.N., Caparon M., Michener M.L., Howard S.C., Pegg L.E., Meyer D.M., De Ciechi P.A., Devine C.S., Casperson G.F. A peptide isolated by phage display binds to ICAM-1 and inhibits binding to LFA-1. Proteins. 26:1996;262-270.
30. Feng Y., Chung D., Garrard L., McEnroe G., Lim D., Scardina J., McFadden K., Guzzetta A., Lam A., Abraham J., Liu D., Endemann G. Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1. J. Biol. Chem. 273:1998;5625-5630.
31. Gursoy R.N., Siahaan T.J. Binding and internalization of an ICAM-1 peptide by the surface receptors of T cells. J. Pept. Res. 53:1999;414-421.
32. Tibbetts S.A., Seetharama Jois D., Siahaan T.J., Benedict S.H., Chan M.A. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T-cell adhesion and function. Peptides. 21:2000;1161-1167.
33. Anderson M.E., Siahaan T.J. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides. 24:2003;487-501. Review.
34. Stanciu L.A., Djukanovic R. The role of ICAM-1 on T-cells in the pathogenesis of asthma. Eur. Respir. J. 11:1998;949-957.
35. Grunstein M.M., Hakonarson H., Maskeri N., Kim C., Chuang S. Intrinsic ICAM-1/LFA-1-activation mediates altered responsiveness of atopic asthmatic airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 278:2000;L1154-L1163.
36. Jiang Z., Woda B.A., Savas L., Fraire A.E. Expression of ICAM-1, VCAM-1, and LFA-1 in adenocarcinoma of the lung with observations on the expression of these adhesion molecules in non-neoplastic lung tissue. Mod. Pathol. 11:1998;1189-1192.
37. Shimoyama S., Gansauge F., Gansauge S., Widmaier U., Oohara T., Beger H.G. Overexpression of intercellular adhesion molecule-1 (ICAM-1) in pancreatic adenocarcinoma in comparison with normal pancreas. Pancreas. 14:1997;181-186.
38. Bo L., Peterson J.W., Mork S., Hoffman P.A., Gallatin W.M., Ransohoff R.M., Trapp B.D. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;1060-1072.
39. Kamoun M. Cellular and molecular parameters in human renal allograft rejection. Clin. Biochem. 34:2001;29-34. Review.
40. Wong J., Kubes P., Zhang Y., Li Y., Urbanski S.J., Bennett C.F., Lee S.S. Role of ICAM-1 in chronic hepatic allograft rejection in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 283:2002;G196-G203.
41. Nicklin S.A., White S.J., Watkins S.J., Hawkins R.E., Baker A.H. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation. 102:2000;231-237.
42. Nicklin S.A., Von Seggern D.J., Work L.M., Pek D.C., Dominiczak A.F., Nemerow G.R., Baker A.H. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol. Ther. 4:2001;534-542.
43. White S.J., Nicklin S.A., Sawamura T., Baker A.H. Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension. 37:2001;449-455.
44. Arap W., Haedicke W., Bernasconi M., Kain R., Rajotte D., Krajewski S., Ellerby H.M., Bredesen D.E., Pasqualini R., Ruoslahti E. Targeting the prostate for destruction through a vascularaddress. Proc. Natl. Acad. Sci. USA. 99:2002;1527-1531.
45. Ruoslahti E., Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18:2000;813-827. Review.
46. Shannon J.P., Silva M.V., Brown D.C., Larson R.S. Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation. J. Pept. Res. 58:2001;140-150.
47. Cai X., Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. USA. 92:1995;6537-6541.
48. Rasmussen U.B., Schreiber V., Schultz H., Mischler F., Schughart K. Tumor cell-targeting by phage displayed peptides. Cancer Gene Ther. 9:2002;606-612.
49. de Kruif J., Terstappen L., Boel E., Logtenberg T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA. 92:1995;3938-3942.
50. Meulemans E.V., Slobbe R., Wasterval P., Ramaekers F.C., van Eys G.J. Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody. J. Mol. Biol. 244:1994;353-360.